KLRS
Kalaris Therapeutics, Inc.
NASDAQ: KLRS · HEALTHCARE · BIOTECHNOLOGY
$5.52
+0.18% today
Updated 2026-04-30
Market cap
$138.41M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.85
Dividend yield
—
52W range
$2 – $12
Volume
0.1M
Kalaris Therapeutics, Inc. (KLRS) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.94M | $-20.16M | $-60.81M | $-106.32M | $-9.78M | $-14.13M | $-67.70M | $-42.98M |
| Capital expenditures | $0.00 | $339000.00 | $235000.00 | $26000.00 | $0.00 | $0.00 | $0.00 | $200000.00 |
| Depreciation | — | $19000.00 | $73000.00 | $1.12M | — | — | — | — |
| Stock-based comp | — | — | — | — | $271000.00 | $148000.00 | $895000.00 | $1.94M |
| Free cash flow | $1.94M | $-20.49M | $-61.05M | $-106.34M | $-9.78M | $-14.13M | $-67.70M | $-43.18M |
| Investing cash flow | — | $-64.64M | $-169.50M | $185.98M | — | — | $95.00M | — |
| Financing cash flow | $22.87M | $120.92M | $291.98M | $232000.00 | $12.78M | $14.24M | $21000.00 | — |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — |